| Name | Title | Contact Details |
|---|
Most patients who are prescribed blockbuster therapies today don`t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher`s platform identifies which drug will work based on the patient`s fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.
Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 11 NIH-designated Diabetes Research Centers in the U.S.
Barc USA is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vidara Therapeutics is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cibus is part of the multi-billion-dollar plant seed industry. Cibus leads the new era of high throughput gene editing technology that can develop plant traits precisely at a fraction of the time and cost of conventional breeding. Cibus is not a seed company. We are a technology company that uses gene editing to develop plant traits. Cibus licenses its traits to seed companies for royalties on seeds that use its traits. Cibus` target market is Productivity Traits” that improve yields, lower input costs such as chemicals and increase the sustainability and profitability of farming. We has a pipeline of six productivity traits including traits for pod shatter reduction, disease resistance and nutrient use efficiency. Cibus` focus is multi-crop traits for the major crops: canola, rice, soybean, wheat, and corn. In other words, traits that can impact global agriculture sustainability at scale. Technology: Gene editing in agriculture is a plant breeding technology. The promise of gene editing in agriculture is the ability to develop plant traits that are indistinguishable from traits developed using conventional breeding but can be developed at a fraction of the time and cost. To many, gene editing represents agriculture`s “analog to digital” technology moment. It is a technology that changes the speed and scale of trait development. Cibus is at the forefront of this technology moment. Our Rapid Trait Development System™ (RTDS®) and Trait Machine™ process represents the first end-to-end semi-automated plant breeding system. Vision: Cibus` vision is to be a pure play trait developer; a technology company whose business is to develop and license plant traits to seed companies in exchange for royalties. The licensing of plant traits and germplasm with quantifiable benefits and strong intellectual property is an integral part of the seed industry. Our goal is to be a leader in this segment of the seed industry.